Abbott agrees to global continuous glucose monitoring litigation settlement with Dexcom
Abbott Park: Abbott has announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.
The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. There are no financial payments associated with the settlement from either Abbott or Dexcom.
"Abbott considers this agreement a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services," Abbott stated.
Details of the settlement are confidential.
Medical Dialogues team had earlier reported that a review application filed by Abbott Healthcare, alleging that the National Pharmaceutical Pricing Authority (NPPA) used lower Price-to-Retailer (PTR) values for competing brands, Prolomet XL 100mg (by Sun Pharma) and Revelol XL 100mg (by IPCA), which resulted in an unjustifiably lower ceiling price for its Metoprolol 100mg modified-release tablets (Supermet XL 100mg IOS), was dismissed by the Department of Pharmaceuticals (DoP).
Abbott is a global healthcare company. Its portfolio of life-changing technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.
